MOG analogues to explore the MCT2 pharmacophore, α-ketoglutarate biology and cellular effects of N-oxalylglycine

Louise Fets; Natalie Bevan; Patrícia M. Nunes; Sebastien Campos; Mariana Silva dos Santos; Emma Sherriff; James I. MacRae; David House; Dimitrios Anastasiou

doi:10.1038/s42003-022-03805-y

Communications Biology (Aug 2022)

MOG analogues to explore the MCT2 pharmacophore, α-ketoglutarate biology and cellular effects of N-oxalylglycine

Louise Fets,
Natalie Bevan,
Patrícia M. Nunes,
Sebastien Campos,
Mariana Silva dos Santos,
Emma Sherriff,
James I. MacRae,
David House,
Dimitrios Anastasiou

Affiliations

Louise Fets: Cancer Metabolism Laboratory, The Francis Crick Institute
Natalie Bevan: Cancer Metabolism Laboratory, The Francis Crick Institute
Patrícia M. Nunes: Cancer Metabolism Laboratory, The Francis Crick Institute
Sebastien Campos: Crick–GSK Biomedical LinkLabs
Mariana Silva dos Santos: Metabolomics Science Technology Platform, The Francis Crick Institute
Emma Sherriff: Crick–GSK Biomedical LinkLabs
James I. MacRae: Metabolomics Science Technology Platform, The Francis Crick Institute
David House: Crick–GSK Biomedical LinkLabs
Dimitrios Anastasiou: Cancer Metabolism Laboratory, The Francis Crick Institute

DOI: https://doi.org/10.1038/s42003-022-03805-y
Journal volume & issue: Vol. 5, no. 1
pp. 1 – 11

Abstract

Read online

Analogs of methyl-oxalylglycine (MOG) were generated as tools to study the monocarboxylate transporter MCT2, an understudied SLC16 family member. These compounds still inhibit prolyl hydroxylases but have minimal metabolic and cytotoxic effects.

Published in Communications Biology

ISSN: 2399-3642 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science: Biology (General)
Website: https://www.nature.com/commsbio/

About the journal